California wants to rescue medical research. Voters must decide if it’s worth $8.4 billion
If passed by voters, the California Immunology Research and Cures Initiative would fund research for immunotherapies to treat and prevent diseases
Newsroom
For press inquiries, please contact press@CAImmunologyBond.com
Historic Immunology Medical Research & Cures Initiative Officially Qualifies for California’s November 2026 Ballot
The Immunology Medical Research & Cures Initiative officially qualified for the November 2026 statewide ballot, with county officials reporting having certified more than 601,317 signatures needed to qualify via random sample. This bond measure gives California voters the opportunity to advance life-saving research and cures for the most debilitating diseases facing millions of California families.
Immunology bond qualifies for November ballot
The $8.4 billion bond is backed by a host of disease advocacy groups like the Alzheimer’s Association and the Parkinson Association of Northern California.
The California Immunology Research and Cures Initiative
Imagine a treatment that doesn’t just ease the tremors for a few hours, but actually slows the progression of disease. Imagine a therapy that catches Parkinson’s early and stops it in its tracks. Imagine a cure in our lifetime.
Immunology bond supporters to submit signatures for November ballot
The $8.4 billion bond is meant to research cures for cancer.
Supporters Submit Signatures to Qualify Historic Immunology Bond for California’s November 2026 Ballot
Today, supporters of the California Immunology Research & Cures Initiative announced they have submitted over 900,000 signatures to qualify the measure for the November 2026 statewide ballot. This $8.4 billion bond will fund California-based nonprofit universities and research institutions to conduct immunology research to develop cutting-edge immunotherapies to prevent and cure debilitating diseases like cancer, Alzheimer’s, and heart disease in our lifetime.
State ballot proposal would approve $8.4 billion in bonds to fund medical research
California nonprofits are working to put an initiative funding immunology research on the November ballot.
New cancer therapy hunts and destroys deadly tumors in major breakthrough study
Off-the-shelf immune cells track and kill pancreatic tumors in preclinical tests
FDA Approves Adding Durvalumab Immunotherapy to Prevent Stomach and Esophageal Cancer Recurrence
A clinical trial led by researchers at Memorial Sloan Kettering Cancer Center (MSK) has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for stomach cancer, cancer of the lower portion of the esophagus, and gastroesophageal junction (GEJ) cancer.
Therapy reawakens immune system to fight pancreatic cancer
Antibody unmasks pancreatic tumors’ ‘sugar-coated’ disguise to keep them from evading immune system